Inger Nijhof

DR.

20122019
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2012 2019

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

van de Donk, N. W. C. J., Casneuf, T., Di Cara, A., Parren, P. W., Zweegman, S., van Kessel, B., Lokhorst, H. M., Usmani, S. Z., Lonial, S., Richardson, P. G., Chiu, C., Mutis, T., Nijhof, I. S. & Sasser, A. K., 1 Feb 2019, In : British Journal of Haematology. 184, 3, p. 475-479 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Marin Soto, J., Broekmans, M., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C., Nijhof, I. S., Mutis, T., Zweegman, S., Lokhorst, H. M. & van de Donk, N. W. C. J., Mar 2018, In : Expert Review of Clinical Immunology. 14, 3, p. 197-206 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

Franssen, L. E., Nijhof, I. S., Couto, S., Levin, M. D., Bos, G. M. J., Broijl, A., Klein, S. K., Ren, Y., Wang, M., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., van der Spek, E., Raymakers, R., Leguit, R. J., Sonneveld, P., Zweegman, S., Lokhorst, H., Mutis, T. & 3 othersThakurta, A., Qian, X. & van de Donk, N. W. C. J., 31 Jul 2018, In : Haematologica. 103, 8, p. e368-e371

Research output: Contribution to journalLetterAcademicpeer-review

Open Access

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S. & Lokhorst, H. M., 1 Jan 2018, In : Drugs. 78, 1, p. 19-37 19 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access